SPY313.78-3.27 -1.03%
DIA259.04-3.96 -1.51%
IXIC10,343.89-89.76 -0.86%

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Europe

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market(NASDAQ: MNOV) announced that it has received a Notice of Intention to Grant from theEuropean Patent Officefor a pending patent application which covers MN-001 (tipelukast) and MN

Benzinga · -
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market(NASDAQ: MNOV) announced that it has received a Notice of Intention to Grant from theEuropean Patent Officefor a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier thanJuly 2034. The allowed claims cover a method of reducing a triglyceride blood level, a method of reducing a total cholesterol blood level, and a method of reducing a low-density lipoprotein (LDL) blood level using MN-001 or MN-002. The allowed claims cover oral administration including liquid and solid dosage forms. Yuichi Iwaki, MD, PhD, President and CEO ofMediciNova, Inc.commented, "We are very pleased to receive notice that this new patent will be granted. As we already have granted patents for similar indications in the U.S., Japan, and China, we believe this additional patent in Europe could substantially increase the potential value of MN-001."